


A




B

Top ZBED2 target genes (Regulon ARACNE TCGA)


| SYMBOL | mode | SYMBOL | mode |
|---------|-----------|----------|-----------|
| FOXA1 | -0.998847 | PDCD1LG2 | 0.9999569 |
| TBX3 | -0.997545 | IL7R | 0.9998151 |
| ZNF711 | -0.997167 | GBP5 | 0.9997805 |
| ZNF620 | -0.996492 | NCF2 | 0.999767 |
| GRM3 | -0.996456 | CAV1 | 0.9997363 |
| ARFGEF3 | -0.996433 | CHST11 | 0.9997176 |
| ZNF10 | -0.996286 | MYO1G | 0.999701 |
| CYP4Z2P | -0.995916 | ADAM19 | 0.9996843 |
| ZFHX2 | -0.995471 | FCGR2A | 0.9996796 |

C




D

INTERFERON GAMMA RESPONSE vs ZBED2 in TCGA



E



F




Figure S8: ZBED2, a novel Basal-associated TF involved in inflammation dampening

A) Overall survival compared to ZBED2 expression in TCGA cohort (Mean +/- sd). B) Top ZBED2 target genes predicted by ARACNE from TCGA regulon. C) Statistical analysis of FOXA1 expression in 15 Pancreatic cell lines (GSE141607). D) Expression correlation of ZBED2 with Interferon Gamma response (Hallmark) in TCGA cohort. E) Viability assay of RT112 and SCaBER upon siRNA treatments ($n=2$). F) 3'seq analysis of RT112 and SCaBER after siRNA treatment against ZBED2 and FOXA1.